RecruitingNCT06436040
Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma
A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma
Sponsor
Tang-Du Hospital
Enrollment
40 participants
Start Date
Jan 24, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
Eligibility
Min Age: 40 YearsMax Age: 80 Years
Inclusion Criteria4
- aged 40 to 80 years;
- had histologically confirmed LUSC with operable locally advanced stage
- no prior anti-tumor therapy; received neoadjuvant immunotherapy consisting of three cycles of anti-PD-1 ICB plus nab-paclitaxel and carboplatin
- pre-treatment tissues
Exclusion Criteria4
- the presence of central nervous system metastases
- the presence of immunodeficiency disease; previous therapies with immunosuppressants within 14 days prior to the initiation of study treatment;
- uncontrolled hypertension
- history of or having pulmonary fibrosis or interstitial lung disease
Interventions
OTHERPathological response assessment
The pathological response classification in our study was based on the histopathologic examination of the surgically resected specimens reviewed by two experienced pathologists.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06436040
Related Trials
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT0710972614 locations
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT072750731 location
Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer
NCT061215056 locations
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
NCT071213741 location
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
NCT062551971 location